Aevi Genomic Medicine, Inc. is a clinical-stage biopharmaceutical company based in Wayne, Pennsylvania, focused on developing novel therapies for pediatric onset and life-altering diseases. The company's lead product candidate, AEVI-002, is an anti-LIGHT monoclonal antibody currently undergoing Phase Ib clinical trials for severe pediatric onset Crohn's disease. Additionally, Aevi is advancing AEVI-005, another monoclonal antibody that is in preclinical research for autoimmune pediatric diseases. The company is also evaluating the anti-seizure activity of AEVI-004 in preclinical models as part of the National Institutes of Health Epilepsy Treatment Screening Program. Aevi Genomic Medicine collaborates with the Center for Applied Genomics at The Children's Hospital of Philadelphia to leverage genomic discoveries in its research and development efforts. Founded in 2000 and formerly known as Medgenics, Aevi Genomic Medicine emphasizes the translation of genomic insights into therapeutic innovations.
Senior Vice President, Research and Development and Site Head, Israel
1 past transactions
neuroFix Therapeutics
Acquisition in 2015
neuroFix Therapeutics, LLC, the developer of NFC-1, a first-in-class, non-stimulant metabotropic glutamate receptor (mGluR) neuromodulator entering Phase 2/3 for the treatment of mGluR network mutation positive Attention Deficit Hyperactivity Disorder (mGluR+ ADHD), as well as neuropsychiatric symptoms resulting from a related rare genetic disorder, 22q11.2 Deletion Syndrome (22q11.2 DS).
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.